Extension of Undrawn US$30 million Facility
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- Long-Term Survival for Acute GvHD Treatment with Remestemcel
- MSB Q1 Financial Results and Operational Highlights
- First Quarter Financial Results on Form 6-K
- Submits New Information to FDA IND File for SR-aGVHD
- MSB Annual Financial Results and Operational Highlights
Later from Mesoblast
- Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
- Half Yearly Report and Accounts
- DREAM HF Trial Published in JACC
- FDA Accepts Mesoblasts BLA Resubmission for Remestemcel-L
- Voluntary Suspension
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast